Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

William G. Wierda; John C. Byrd; Jeremy S. Abramson; Syed F. Bilgrami; Greg Bociek; Danielle Brander; Jennifer Brown; Asher A. Chanan-Khan; Julio C. Chavez; Steve E. Coutre; Randall S. Davis; Christopher D. Fletcher; Brian Hill; Brad S. Kahl; Manali Kamdar; Lawrence D. Kaplan; Nadia Khan; Thomas J. Kipps; Shuo Ma; Sami Malek; Anthony Mato; Claudio Mosse; Vishala T. Neppalli; Mazyar Shadman; Tanya Siddiqi; Deborah Stephens; Nina Wagner; Mary A. Dwyer; Hema Sundar

doi:10.6004/jnccn.2019.0002

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami MalekAnthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer, Hema Sundar

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter’s transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.

Original language	English (US)
Pages (from-to)	12-20
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2019.0002
State	Published - Jan 2019

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2019.0002

Cite this

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., ... Sundar, H. (2019). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. JNCCN Journal of the National Comprehensive Cancer Network, 17(1), 12-20. https://doi.org/10.6004/jnccn.2019.0002

@article{0520409d289040dca954c47cac426246,

title = "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019",

abstract = "Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter{\textquoteright}s transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.",

author = "Wierda, {William G.} and Byrd, {John C.} and Abramson, {Jeremy S.} and Bilgrami, {Syed F.} and Greg Bociek and Danielle Brander and Jennifer Brown and Chanan-Khan, {Asher A.} and Chavez, {Julio C.} and Coutre, {Steve E.} and Davis, {Randall S.} and Fletcher, {Christopher D.} and Brian Hill and Kahl, {Brad S.} and Manali Kamdar and Kaplan, {Lawrence D.} and Nadia Khan and Kipps, {Thomas J.} and Shuo Ma and Sami Malek and Anthony Mato and Claudio Mosse and Neppalli, {Vishala T.} and Mazyar Shadman and Tanya Siddiqi and Deborah Stephens and Nina Wagner and Dwyer, {Mary A.} and Hema Sundar",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2019",

month = jan,

doi = "10.6004/jnccn.2019.0002",

language = "English (US)",

volume = "17",

pages = "12--20",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

Wierda, WG, Byrd, JC, Abramson, JS, Bilgrami, SF, Bociek, G, Brander, D, Brown, J, Chanan-Khan, AA, Chavez, JC, Coutre, SE, Davis, RS, Fletcher, CD, Hill, B, Kahl, BS, Kamdar, M, Kaplan, LD, Khan, N, Kipps, TJ, Ma, S, Malek, S, Mato, A, Mosse, C, Neppalli, VT, Shadman, M, Siddiqi, T, Stephens, D, Wagner, N, Dwyer, MA & Sundar, H 2019, 'Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 1, pp. 12-20. https://doi.org/10.6004/jnccn.2019.0002

TY - JOUR

T1 - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

AU - Wierda, William G.

AU - Byrd, John C.

AU - Abramson, Jeremy S.

AU - Bilgrami, Syed F.

AU - Bociek, Greg

AU - Brander, Danielle

AU - Brown, Jennifer

AU - Chanan-Khan, Asher A.

AU - Chavez, Julio C.

AU - Coutre, Steve E.

AU - Davis, Randall S.

AU - Fletcher, Christopher D.

AU - Hill, Brian

AU - Kahl, Brad S.

AU - Kamdar, Manali

AU - Kaplan, Lawrence D.

AU - Khan, Nadia

AU - Kipps, Thomas J.

AU - Ma, Shuo

AU - Malek, Sami

AU - Mato, Anthony

AU - Mosse, Claudio

AU - Neppalli, Vishala T.

AU - Shadman, Mazyar

AU - Siddiqi, Tanya

AU - Stephens, Deborah

AU - Wagner, Nina

AU - Dwyer, Mary A.

AU - Sundar, Hema

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Publisher Copyright: © JNCCN—Journal of the National Comprehensive Cancer Network.

PY - 2019/1

Y1 - 2019/1

N2 - Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter’s transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.

AB - Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter’s transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.

UR - http://www.scopus.com/inward/record.url?scp=85060137075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060137075&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0002

DO - 10.6004/jnccn.2019.0002

M3 - Article

C2 - 30659125

AN - SCOPUS:85060137075

SN - 1540-1405

VL - 17

SP - 12

EP - 20

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 1

ER -

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this